
Regentis Biomaterials Advances GelrinC Toward U.S. Approval and European Commercialization
Regentis Biomaterials is progressing its off-the-shelf hydrogel implant GelrinC through a pivotal U.S. Phase III trial and preparing for European commercialization, targeting a $3 billion knee cartilage repair market.
Read full story
























